US$ 23.43
glp 1 ckd GLP-1 receptor agonists in patients with chronic kidney disease and either overweight or obesity GLP1 Receptor Agonists vs SGLT2-I
Description
Tirzepatide has a dual-action mechanism, targeting multiple hormone pathways

Schimmer S

Challenges and management of liver cirrhosis: Practical issues in the therapy of patients with cirrhosis due to NAFLD and NASH

Maintenance is most successful when it is treated as an active phase of care, not as the end of treatment

Arrestins as regulators of kinases and phosphatases
Er zijn situaties waarin GLP-1 middelen worden afgeraden
